Latest News and Press Releases

Under the agreement, Multimeric will license the rights to all multimeric fusion proteins containing TNFSFs which are covered by Topotarget’s issued and pending patents in Europe, US, Canada, Japan,...

    Interim report for Q3...

    Rapport for 3. kvartal...

   Registreringsstudie i henhold til  ”Special Protocol Assessment” fra FDA FDA har tildelt ”Fast Track-status” og ”Orphan Drug-status” Forventet indsendelse af...

  Registrational trial under a Special Protocol Assessment by FDA Granted Fast Track and Orphan Drug Designation by FDA On track to file New Drug Application in...

København, Danmark – 13. september 2011 – Topotarget A/S (NASDAQ OMX: TOPO.CO) har i dag meddelt, at kliniske data (videnskablige resuméer) vil blive præsenteret på The European Multidisciplinary...

Copenhagen, Denmark – 13 September, 2011 – Today Topotarget A/S (NASDAQ OMX: TOPO.CO) announcedthat clinical data on belinostat will be presented at The European Multidisciplinary Cancer Congress in...

   Copenhagen, Denmark – 29 August 2011 – Today Topotarget A/S (NASDAQ OMX: TOPO.CO) has held the extraordinary general meeting.   At Topotarget A/S’ extraordinary general...

  København, Danmark – 29. august 2011 – Topotarget A/S (NASDAQ OMX: TOPO.CO) har i dag afholdt ekstraordinær generalforsamling.   På Topotarget A/S’ ekstraordinære generalforsamling...

Vedtægter for Topotarget A/S er vedhæftet som PDF-fil....